The DOI matches its Crossref record.
Cannabis-based medicinal products: summary of NICE guidance
Abstract
### What you need to know In September 2018, in light of the UK chief medical officer’s review and in response to the Advisory Council on the Misuse of Drugs advice, ministers in the UK announced changes to the existing regulations on cannabis-based medicinal products (CBMPs). CBMPs would be rescheduled from Schedule 1 of the Misuse of Drugs Regulations 200112 to Schedule 2 controlled drugs and that prescribing would be restricted to doctors on the Specialist Register of the General Medical Council (GMC). Rescheduling allows CBMPs to be legally prescribed. However, many CBMPs currently do not have marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA), and so existing prescribing guidance and governance arrangements in place for unlicensed medicines continue to apply. Unlicensed medications should not be considered as first line treatments and should be used only when there is …
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Cannabinoids are costly for patients.
“A large number of patients need to be treated to achieve a clinical benefit [81] and they are costly for patients [88].”
From Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits (2025) · cites this paper as [88]
Nabiximols are only recommended if other treatments are ineffective.
“Nabiximols are only recommended if other treatments are ineffective, and a 4-week trial produces at least a 20% reduction in spasticity-related symptoms [88].”
From Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits (2025) · cites this paper as [88]
A 4-week trial of nabiximols produces at least a 20% reduction in spasticity-related symptoms.
“Nabiximols are only recommended if other treatments are ineffective, and a 4-week trial produces at least a 20% reduction in spasticity-related symptoms [88].”
From Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits (2025) · cites this paper as [88]
Citations
Cited by
Sorted by citations
Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits
Hoch, E., Volkow, N. D., Friemel, C. M., Lorenzetti, V., Freeman, T. P., & Hall, W. (2025) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01880-2 · Cited by 139
“Nabiximols are only recommended if other treatments are ineffective, and a 4-week trial produces at least a 20% reduction in spasticity-related symptoms [88].”
Metadata
- Authors
- Chang-Douglass, S., Mulvihill, C., & Pilling, S.
- Affiliations
- National Institute for Health and Care Excellence (GB)
- University College London (GB)
- Corresponding author
- Mulvihill, Caroline
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2020-04-21
- Volume
- 369
- Pages
- m1108
- ISSN
- 1756-1833 (ISSN-L)
- OpenAlex
- W3016770638
- Cited by
- 18
- References
- 0
- Citations by year
- 2024: 3 · 2023: 4 · 2022: 3 · 2021: 7 · 2020: 1
- FWCI
- 2.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.bmj.com/company/legal-information/terms-conditions/legal-information/tdm-licencepolicy (tdm)
- Locations
- BMJ (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Complementary and alternative medicine › Complementary and Alternative Medicine Studies
- Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
- Keywords
- cannabis-based medicinal products, NICE guidelines, controlled substances, prescribing restrictions, unlicensed medicines, drug approval, specialist prescribing
- MeSH terms
- Drug Resistant Epilepsy, Decision Making, Shared, Antiemetics, Antineoplastic Agents, Cannabidiol, Drug and Narcotic Control, Epilepsies, Myoclonic, United Kingdom, Humans, Multiple Sclerosis, Muscle Spasticity, Nausea, Specialization, Dronabinol, Vomiting, Practice Guidelines as Topic, Needs Assessment, Physicians, Primary Care, Chronic Pain, Cannabinoid Receptor Agonists, Medical Marijuana, Lennox Gastaut Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
